Public Funding for Telonostix LTD.

A case study for Innovate UK's Precision Medicine Catapult (PMC) (whose activities now fall under the Medicines Discvovery Catapult (MDC)), TeloNostiX Ltd's prognostic test for Chronic Lymphocytic Leukaemia (CLL) through Single Telomere Length Analysis (STELA) helps address two significant global healthcare challenges: 1) patient stratification and 2) precision medicine (a letter in support of the project from the PMC is available upon request). We seek funding to achieve two specific objectives critical to the development of our technology: (i) Demonstrate the technical feasibility of telomere testing in the routine clinical management of CLL patients by performing a logistical evaluation within an operational environment; (ii) Create a financial justification for NHS adoption of STELA by undertaking health economics modelling. The key focus will be to evaluate the potential for using STELA to stratify CLL patients into risk groups based on whether they will undergo clinical progression and require treatment. This analysis will consist of a literature review, evidence synthesis, and care pathway analysis. We will also engage with a global distributor of telomere tests and analyse the cancer prognostics market using current market reports to further quantify the business opportunity.